Royal Bank of Canada’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Royal Bank of Canada’s Portfolio EFTR Stock Details EFTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-546	Closed	–	–	7741
2024 Q2	$0	Buy	546 +114	+26%	+$271	﹤0.01%	7715
2024 Q1	$6K	Buy	432 +426	+7,100%	+$5.1K	﹤0.01%	6417
2023 Q4	$0	Sell	6 -10	-63%	-$134	﹤0.01%	7743
2023 Q3	$0	Hold	16	–	–	﹤0.01%	7773
2023 Q2	$0	Buy	+16	New	+$270	﹤0.01%	7793

Other funds holding EFTR

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Royal Bank of Canada's EFTR Position: Q3 2024 in Review

Royal Bank of Canada sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q3 2024, closing a stake of 546 shares.

Royal Bank of Canada first reported a position in EFTR in Q2 2023 and held it in 5 quarters. The position peaked at $6K in Q1 2024. 3 funds tracked by Wall St. Rank hold EFTR as of Q3 2024.

Royal Bank of Canada reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Royal Bank of Canada sold 546 eFFECTOR Therapeutics, Inc. Common Stock shares in Q3 2024.
Royal Bank of Canada first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q2 2023 and held it in 5 quarters.
Royal Bank of Canada's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $6K in Q1 2024.
3 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Royal Bank of Canada's 13F filing for Q3 2024, filed 14 Nov 2024.